info@seagull-health.com
SeagullHealth
search
Ramucirumab(Cyramza)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Cyramza(Ramucirumab) Instructions:Uses,Dosage, Side Effects
CYRAMZA (ramucirumab) is a fully human monoclonal antibody that functions as a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist. By selectively binding to VEGFR2, CYRAMZA inhibits ligand-induced receptor activation, thereby blocking angiogenesis, a critical process in tumor growth and metastasis. This targeted mechanism underpins its clinical utility across multiple solid tumor types.
Approved for intravenous administration, CYRAMZA is utilized either as monotherapy or in combination with established chemotherapeutic regimens, depending on the cancer type and line of therapy. Its clinical application is supported by robust evidence from multiple phase III trials, demonstrating efficacy in improving outcomes for patients with advanced gastric, lung, colorectal, and liver cancers. The safety profile and dosing recommendations are tailored to each indication, with careful monitoring for specific adverse events such as hypertension, proteinuria, and hemorrhagic complications.
Advanced or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma, as monotherapy or with paclitaxel, after progression on or after fluoropyrimidine- or platinum-based chemotherapy.
Metastatic non-small cell lung cancer (NSCLC):
In combination with erlotinib for first-line treatment in patients with EGFR exon 19 deletions or exon 21 (L858R) mutations;
In combination with docetaxel for patients with disease progression on or after platinum-based chemotherapy (after progression on EGFR/ALK-targeted therapy if applicable);
Metastatic colorectal cancer (mCRC), in combination with FOLFIRI, after progression on or after bevacizumab, oxaliplatin, and a fluoropyrimidine;
Hepatocellular carcinoma (HCC), as monotherapy, in patients with alpha fetoprotein (AFP) ≥ 400 ng/mL who have been treated with sorafenib.
1. Gastric cancer: 8 mg/kg every 2 weeks, over 60 minutes (subsequent infusions may be over 30 minutes if tolerated).
2. NSCLC: 10 mg/kg every 2 weeks with erlotinib, or 10 mg/kg on day 1 of a 21-day cycle with docetaxel.
3. Colorectal cancer: 8 mg/kg every 2 weeks prior to FOLFIRI.
4. HCC: 8 mg/kg every 2 weeks.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
